Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis

Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival

(2014) H. A. Luchman et al.   CLINICAL CANCER RESEARCH

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer

(2013) T. Powles et al.   ANNALS OF ONCOLOGY

Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice

(2013) Alessio Giubellino et al.   ENDOCRINOLOGY

Evolutionarily conserved regulation of TOR signalling

(2013) T. Takahara et al.   JOURNAL OF BIOCHEMISTRY

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2013) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

(2013) Hao Zhang et al.   PLoS One

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models

(2012) Yesim Gökmen-Polar et al.   BREAST CANCER RESEARCH AND TREATMENT

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

(2012) A. W. Griffioen et al.   CLINICAL CANCER RESEARCH

Axl is essential for VEGF-A-dependent activation of PI3K/Akt

(2012) Guo-Xiang Ruan et al.   EMBO JOURNAL

Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin

(2012) Keita Saito et al.   PLoS One

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors

(2011) B. L. Falcon et al.   CANCER RESEARCH

Focal adhesion kinase regulation of neovascularization

(2011) Kishore K. Wary et al.   MICROVASCULAR RESEARCH

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Sequential use of targeted agents in the treatment of renal cell carcinoma

(2010) Thomas E. Hutson et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A 164 –Driven Angiogenesis, in Part by Blocking S6Kinase

(2009) Qi Xue et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

(2009) Anil Kapoor et al.   CANCER

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

(2008) W. Cacheux et al.   ANNALS OF ONCOLOGY

Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival

(2008) P. C. McDonald et al.   CANCER RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE